News

The novel method of administration is a first of its kind for the common chronic eye condition.

Travel issues related to COVID-19 were responsible for the delay in the approval of the Biologics License Application.

The approval was supported by promising phase 3 data of the VOLTAIRE-X clinical trial.

The letter pointed to a single deficiency related to an open inspection issue at a third-party facility.

New data reveals that the pandemic led to significantly less medicines being taken by pediatric patients during the first lockdown in Finland.

Dr. Simona Bujoreanu explains the importance of acknowledging the psychological aspect of chronic pain management.

Offspring born to mothers with any diabetes diagnosis during pregnancy were more likely to develop any psychiatric disorder or specific disorders, compared to their unexposed peers.

The first iteration of Crisis Point addresses the obesity crisis in the United States and beyond, with expert interviews and discussion.

The new indication makes the quadrivalent Seqirus flu shot available for every US-eligible patient age group.

Data from the PAUSE clinical trial reveals that more participants experienced psoriasis relapse in the abatacept group than the ustekinumab group.

C difficile was found on 45% of shoe soles and 26.2% of private residences.

Dr. Robert Califf previously ran the FDA in 2016 and 2017 under former President Barack Obama.

Executive function can include working memory, behavioral inhibition, and cognitive flexibility.

Dr. Simona Bujoreanu discusses the different types of barriers that are faced when treating chronic pain in pediatric patients.

The retina field is equipped with ideal therapy and research informing implementation. Now it needs greater patient buy-in.

Assessment from a patient survey showed an association between increased rates of injection treatment and increased restriction on usual activity for patients.

Data show the overall risk difference between the first and second doses of BNT162b2 was 1.76 per 100,000 persons.

Rishi P. Singh, MD, discusses new VISTA/VIVID data showing what really influences a patients' likelihood and time to DME resolution when treated with aflibercept.

The 4 factors included baseline body mass index, fibrosis-4 index, albumin level at SVR, and alpha-foetoprotein level at SVR.

In the primary endpoint, patients with severe HF had a 20% risk reduction compared to no significant treatment benefit in patients without severe HF.

Potential donors are denied for a variety of reasons, including high body mass index, underlying chronic illnesses, or the use of antibiotics within 3 months.

The indication came via the Premarket Tobacco Product Application, which requires evidence of public health benefit and company agreement to post-marketing strategies that avoid young users.

Theodore Leng, MD, MS, defines the trends of patient discontinuation, and how direct caregivers may help to reduce risk of losing patients.

Investigators reported a 3% difference in clinically relevant bleeding in participants treated with rivaroxaban and aspirin.

Arshad Khanani, MD, MA, explains how new measures made available to ophthalmology will help address a quickly growing patient population.

Hospitalization rates from the baseline to Cycle 3 decreased 19% from 0.52/person/year to 0.43/person/year

Proposed new guidelines recommended against low-dose aspirin use for primary prevention of CVD in adults age 60 years or older, citing adverse effects.

There were no episode of gastrointestinal bleeding, transfusion of packed red blood cells, or octreotide infusions observed.